AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

​​​​​​​AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.